192 related articles for article (PubMed ID: 27533467)
1. Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.
Underbayev C; Kasar S; Ruezinsky W; Degheidy H; Schneider JS; Marti G; Bauer SR; Fraidenraich D; Lightfoote MM; Parashar V; Raveche E; Batish M
Oncotarget; 2016 Sep; 7(38):60986-60999. PubMed ID: 27533467
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL).
Kasar S; Underbayev C; Hassan M; Ilev I; Degheidy H; Bauer S; Marti G; Lutz C; Raveche E; Batish M
PLoS One; 2016; 11(3):e0149331. PubMed ID: 26959643
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
Kasar S; Underbayev C; Yuan Y; Hanlon M; Aly S; Khan H; Chang V; Batish M; Gavrilova T; Badiane F; Degheidy H; Marti G; Raveche E
Oncogene; 2014 Jun; 33(25):3307-15. PubMed ID: 23995789
[TBL] [Abstract][Full Text] [Related]
4. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.
Salerno E; Scaglione BJ; Coffman FD; Brown BD; Baccarini A; Fernandes H; Marti G; Raveche ES
Mol Cancer Ther; 2009 Sep; 8(9):2684-92. PubMed ID: 19723889
[TBL] [Abstract][Full Text] [Related]
5. The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.
Salerno E; Yuan Y; Scaglione BJ; Marti G; Jankovic A; Mazzella F; Laurindo MF; Despres D; Baskar S; Rader C; Raveche E
Cytometry B Clin Cytom; 2010; 78 Suppl 1(Suppl 1):S98-109. PubMed ID: 20839343
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
Braga TV; Evangelista FCG; Gomes LC; Araújo SSDS; Carvalho MDG; Sabino AP
Biomed Pharmacother; 2017 Aug; 92():864-869. PubMed ID: 28599250
[TBL] [Abstract][Full Text] [Related]
7. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.
Raveche ES; Salerno E; Scaglione BJ; Manohar V; Abbasi F; Lin YC; Fredrickson T; Landgraf P; Ramachandra S; Huppi K; Toro JR; Zenger VE; Metcalf RA; Marti GE
Blood; 2007 Jun; 109(12):5079-86. PubMed ID: 17351108
[TBL] [Abstract][Full Text] [Related]
8. Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia.
Kasar S; Salerno E; Yuan Y; Underbayev C; Vollenweider D; Laurindo MF; Fernandes H; Bonci D; Addario A; Mazzella F; Raveche E
Genes Immun; 2012 Feb; 13(2):109-19. PubMed ID: 21881595
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of miR-15a/16-1 and miR-497/195 clusters in immune cell development and homeostasis.
Hutter K; Rülicke T; Drach M; Andersen L; Villunger A; Herzog S
FEBS J; 2021 Mar; 288(5):1533-1545. PubMed ID: 32705746
[TBL] [Abstract][Full Text] [Related]
10. Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).
Hanlon K; Rudin CE; Harries LW
PLoS One; 2009 Sep; 4(9):e7169. PubMed ID: 19779621
[TBL] [Abstract][Full Text] [Related]
11. Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.
Cutrona G; Matis S; Colombo M; Massucco C; Baio G; Valdora F; Emionite L; Fabris S; Recchia AG; Gentile M; Neumaier CE; Reverberi D; Massara R; Boccardo S; Basso L; Salvi S; Rosa F; Cilli M; Zupo S; Truini M; Tassone P; Calabrese M; Negrini M; Neri A; Morabito F; Fais F; Ferrarini M
Leukemia; 2017 Sep; 31(9):1894-1904. PubMed ID: 28053325
[TBL] [Abstract][Full Text] [Related]
12. Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia.
Humplikova L; Kollinerova S; Papajik T; Pikalova Z; Holzerova M; Prochazka V; Divoka M; Modriansky M; Indrak K; Jarosova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):284-93. PubMed ID: 24026141
[TBL] [Abstract][Full Text] [Related]
13. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
14. All you need is a Mir-acle: the role of nontranslated RNAs in the suppression of B cell chronic lymphocytic leukemia.
Lichter P
Cancer Cell; 2010 Jan; 17(1):3-4. PubMed ID: 20129242
[TBL] [Abstract][Full Text] [Related]
15. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
D'Abundo L; Callegari E; Bresin A; Chillemi A; Elamin BK; Guerriero P; Huang X; Saccenti E; Hussein EMAA; Casciano F; Secchiero P; Zauli G; Calin GA; Russo G; Lee LJ; Croce CM; Marcucci G; Sabbioni S; Malavasi F; Negrini M
Oncogene; 2017 Nov; 36(47):6617-6626. PubMed ID: 28783166
[TBL] [Abstract][Full Text] [Related]
16. miR-15 and miR-16 induce apoptosis by targeting BCL2.
Cimmino A; Calin GA; Fabbri M; Iorio MV; Ferracin M; Shimizu M; Wojcik SE; Aqeilan RI; Zupo S; Dono M; Rassenti L; Alder H; Volinia S; Liu CG; Kipps TJ; Negrini M; Croce CM
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13944-9. PubMed ID: 16166262
[TBL] [Abstract][Full Text] [Related]
17. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model.
Scaglione BJ; Salerno E; Balan M; Coffman F; Landgraf P; Abbasi F; Kotenko S; Marti GE; Raveche ES
Br J Haematol; 2007 Dec; 139(5):645-57. PubMed ID: 17941951
[TBL] [Abstract][Full Text] [Related]
18. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
19. Complete miRNA-15/16 loss in mice promotes hematopoietic progenitor expansion and a myeloid-biased hyperproliferative state.
Ng A; Lovat F; Shih AJ; Ma Y; Pekarsky Y; DiCaro F; Crichton L; Sharma E; Yan XJ; Sun D; Song T; Zou YR; Will B; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2023 Oct; 120(43):e2308658120. PubMed ID: 37844234
[TBL] [Abstract][Full Text] [Related]
20. miR-15b/16-2 deletion promotes B-cell malignancies.
Lovat F; Fassan M; Gasparini P; Rizzotto L; Cascione L; Pizzi M; Vicentini C; Balatti V; Palmieri D; Costinean S; Croce CM
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11636-41. PubMed ID: 26324892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
